Odonate Therapeutics Stock

Odonate Therapeutics P/E 2024

Odonate Therapeutics P/E

-17.69

Ticker

ODTC

ISIN

US6760791060

WKN

A2H9FC

As of Oct 1, 2024, Odonate Therapeutics's P/E ratio was -17.69, a 49.03% change from the -11.87 P/E ratio recorded in the previous year.

The Odonate Therapeutics P/E history

Odonate Therapeutics Aktienanalyse

What does Odonate Therapeutics do?

Odonate Therapeutics Inc is a biopharmaceutical company that specializes in the development of medications to assist patients with serious illnesses. The company was founded in 2013 by a team of experienced scientists, doctors, and experts from the pharmaceutical industry, with the goal of creating a revolutionary alternative to conventional cancer therapy. The idea was to develop a therapy that minimizes the unwanted effects of chemotherapy and radiation, while still being equally effective in fighting cancer. The business model of Odonate Therapeutics is based on the development of medications that specifically target certain substances in order to achieve maximum effectiveness and efficiency. The company primarily focuses on the research and development of cancer therapeutics and has already brought several innovative products to market, which are currently in the clinical testing phase. One of the main areas of Odonate Therapeutics' research and development is medication based on taxanes. Taxanes are a class of medications known for their effectiveness in fighting cancer. Odonate Therapeutics has the innovative idea of combining these substances with others to minimize the side effects of taxanes. The goal is to create a new generation of medications that offer a targeted approach to fighting cancer. Another focus of Odonate Therapeutics is the development of medications for the treatment of patients with breast cancer. The company has already conducted several testing phases for its flagship product, Odonate Therapeutics' Tesetaxel. Tesetaxel is a novel chemotherapy drug that aims to achieve higher efficacy with lower side effects. The results of the studies have been promising and have the potential to change the lives of patients with breast cancer. Another product developed by Odonate Therapeutics is the medication Odonate Therapeutics' Ladiratuzumab Vedotin. This is a cancer drug that was developed in phase 1 studies and is suitable for the treatment of patients with solid tumors. In this study, it has been shown to be well-tolerated and has shown promising results in fighting cancer cells. Over the past few years, Odonate Therapeutics Inc has achieved an impressive track record by developing innovative medications that have the potential to improve patients' lives. The research and development of cancer therapeutics is an area that requires increasing attention, as cancer remains one of the leading causes of death worldwide. Odonate Therapeutics aims to address this challenge by developing innovative products that meet the needs of patients. Overall, Odonate Therapeutics has quickly established a strong reputation in the biotech industry, and the company appears to be on a good path. The company has many promising medication pipeline programs, and the management team consists of experienced leaders focused on developing therapeutics and improving patients' quality of life. Odonate Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Odonate Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Odonate Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Odonate Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Odonate Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Odonate Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Odonate Therapeutics stock

What is the price-to-earnings ratio of Odonate Therapeutics?

The price-earnings ratio of Odonate Therapeutics is currently -17.69.

How has the price-earnings ratio of Odonate Therapeutics changed compared to last year?

The price-to-earnings ratio of Odonate Therapeutics has increased by 49.03% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Odonate Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Odonate Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Odonate Therapeutics affect the company?

An increase in the price-earnings ratio of Odonate Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Odonate Therapeutics affect the company?

A decrease in the price-earnings ratio of Odonate Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Odonate Therapeutics?

Some factors that influence the price-earnings ratio of Odonate Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Odonate Therapeutics pay?

Over the past 12 months, Odonate Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Odonate Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Odonate Therapeutics?

The current dividend yield of Odonate Therapeutics is .

When does Odonate Therapeutics pay dividends?

Odonate Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Odonate Therapeutics?

Odonate Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Odonate Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Odonate Therapeutics located?

Odonate Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Odonate Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Odonate Therapeutics from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Odonate Therapeutics pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Odonate Therapeutics in the year 2023?

In the year 2023, Odonate Therapeutics distributed 0 USD as dividends.

In which currency does Odonate Therapeutics pay out the dividend?

The dividends of Odonate Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Odonate Therapeutics

Our stock analysis for Odonate Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Odonate Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.